Blinatumomab Antibody is a research-grade biosimilar monoclonal antibody targeting CD19. Format: (scFv-kappa-heavy)-(scFv-heavy-kappa) (mouse host). Reactivity: Human. Supplied as a liquid in 30 mM Histidine, pH5.8, 10% sucrose, 0.02% Tween80. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia.